MedTrace Logo

A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer

NCT02595450 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 299

Last updated 2016-01-25

Study results available
· View outcomes & findings →

Summary

This is a non-interventional, open label, single arm, multicenter study to assess the safety and efficacy of erlotinib in participants with non-small cell lung cancer.

Conditions

Interventions

DRUG

Erlotinib

Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
35 Years
Max Age
86 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02595450 on ClinicalTrials.gov